STOCK TITAN

Dynavax Technologies Corp. - DVAX STOCK NEWS

Welcome to our dedicated news page for Dynavax Technologies (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dynavax Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dynavax Technologies's position in the market.

Rhea-AI Summary
Dynavax Technologies Corporation reported record quarterly HEPLISAV-B vaccine net product revenue of $56 million, a 73% year-over-year increase. Full year HEPLISAV-B net product revenue guidance was raised to $200 - $215 million. Cash and investments increased to $682 million at quarter end. The company expects positive free cash flow for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
-
Rhea-AI Summary
Dynavax Technologies Corporation reported a 109% increase in net product revenue for their HEPLISAV-B vaccine in Q1 2023. They also reaffirmed their full-year revenue guidance of $165-$185 million, representing a growth of 30-47%. The company's balance sheet is strong with $652 million in cash and investments. They expect positive free cash flow in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences earnings
Dynavax Technologies Corp.

Nasdaq:DVAX

DVAX Rankings

DVAX Stock Data

1.55B
123.09M
0.31%
98.02%
13.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Emeryville

About DVAX

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.